Could a gut drug ease long COVID? new trial tests larazotide in kids and adults
NCT ID NCT05747534
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This study tests whether the drug larazotide can safely reduce Long COVID symptoms in 107 people aged 7 to 50. Participants take either the drug or a placebo four times a day for 21 days. The goal is to see if the drug helps with symptoms like fatigue, brain fog, and breathing trouble.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-ACUTE COVID-19 SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.